Updated menopause guidance includes discussion aid to support conversations about HRT
Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.
The guideline aims to support healthcare professionals by providing them with information they need to support evidence-based decisions about treatment choices, as well as information and support about menopause.
The guideline recognises that the experience of menopause varies considerably. For those over 40 seeking treatment for common symptoms such as hot flushes and night sweats (known as vasomotor symptoms) or symptoms such as vaginal dryness, the guideline advises tailoring information about benefits and risks based on age, individual circumstances, and any potential risk factors. It emphasises the importance of only prescribing hormone replacement therapy (HRT) within licensed doses.
While HRT is the most effective treatment for vasomotor symptoms, the guideline also recommends that for people over 40 healthcare professionals should consider menopause-specific cognitive behavioural therapy (CBT) as an option for vasomotor symptoms associated with menopause in addition to HRT. It can also be considered for people for whom HRT is not advised, or for those who prefer not to take HRT.
Although HRT is effective for symptoms, it should not be used for the prevention of cardiovascular disease or dementia.
We have also today published a new discussion aid to support shared decision making about HRT, focusing on the key risks and benefits to consider. The guideline clarifies that whilst HRT has some risks, it is unlikely to increase or decrease overall life expectancy.
The guideline also clarifies when cognitive behavioural therapy (CBT) may be of benefit for vasomotor symptoms and may also benefit sleep and mood.
The updated guideline also includes new recommendations on the management of genitourinary symptoms such as vaginal dryness, painful sex and vaginal discomfort or irritation. The guideline includes a visual summary so health professionals treating women with and without a history of breast cancer can find the options that best suit them.